Research Programs and Centers
The William S. Rowe Division of Rheumatology at Cincinnati Children’s Hospital Medical Center is involved in numerous cutting-edge research program level efforts to better our understanding of pediatric rheumatic diseases.
NIAMS P-30: To Promote Cutting-Edge Research Through Cooperative Efforts
The Cincinnati Rheumatic Diseases Core Center (P30 AR47363) has been funded since 2001. The Division of Rheumatology at Cincinnati Children's Hospital Medical Center is focused on studying rheumatic diseases of childhood. In keeping with this tradition, the goals of the center are to promote and foster cutting-edge research that will further the understanding of the pathophysiologies of the rheumatic diseases, lead to novel therapeutic approaches to the treatment of these diseases, and change the outcome for children suffering from them.
For more information about this study, contact Susan Thompson, PhD.
NIAMS P-60: Multidisciplinary Clinical Research Center (MCRC): To Provide Needed Expertise for the Division of Rheumatology That Are Not Available at the Laboratory Level
The P-60 Multidisciplinary Clinical Research Center provides resources to the Division of Rheumatology and the research base that would be impossible for any single laboratory to provide on its own. These services have markedly and positively impacted on the growth of rheumatology in both Cincinnati Children’s and in the close collaborations within the MCRC. Collaboration of the MCRC with other researchers and organizations as well as the MCRC Research Base have worked synergistically to promote research in pediatric rheumatology. The Division of Rheumatology has expanded substantially as a result of the award of the P60 centers, and this expansion is particularly notable in terms of faculty, papers, grant support and fellows.
For more information about this study, contact Daniel Lovell, MD, MPH.
NIAMS P-01: To Identify Gene Expression Patterns to Use as New Markers of Disease
Through the P-01 Program for Gene Expression in Pediatric Arthritis, the level of mRNA of all genes in blood cells will be measured by microarray analysis to identify patterns specific to JIA patients, specific JIA subtypes, response to treatment or outcome variables. These expression markers may provide a molecular basis for treatment decisions at early stages of disease.
For more information about this study, contact Susan Thompson, PhD or Daniel Lovell, MD, MPH.
NIAMS Contract: To Identify the Genetic Components of JIA
JIA is the most common chronic inflammatory pediatric rheumatic disease with about 80,000 cases in the United States alone. This autoimmune disease is categorized as a complex genetic trait. Genetic studies have identified both HLA and non-HLA candidate genes and several chromosome regions for potential contribution to either JIA susceptibility or resistance. Together, the collection of DNA from the JIA Affected Sib Pair Registry (more than 200 families) and a cohort of more than 1,300 simplex JIA families, the developments of the Human Genome Project, the HapMap Project and technical advances in SNP genotyping make this project possible.
For more information about this study, contact Susan Thompson, PhD.
NIAMS Sib Pair Registry: To Identify Families with more than one child with JIA for Research Purposes
This JIA-affected sib-pair registry, sponsored by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), an institute of the US National Institutes of Health), is a unique and powerful resource for investigators seeking to understand the causes and outcomes of JIA. Collaborative and synergistic use of registry resources are encouraged as a route to more effective research into the causes of JIA and improvement of treatment.
For more information about this study or to enroll a family, contact Susan Thompson, PhD.
